MX2008011312A - Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos. - Google Patents

Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos.

Info

Publication number
MX2008011312A
MX2008011312A MX2008011312A MX2008011312A MX2008011312A MX 2008011312 A MX2008011312 A MX 2008011312A MX 2008011312 A MX2008011312 A MX 2008011312A MX 2008011312 A MX2008011312 A MX 2008011312A MX 2008011312 A MX2008011312 A MX 2008011312A
Authority
MX
Mexico
Prior art keywords
treatment
neurodegenerative disorders
meridamycin
analogues
meridamycin analogues
Prior art date
Application number
MX2008011312A
Other languages
English (en)
Inventor
Kevin Pong
Edmund Idris Graziani
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2008011312A publication Critical patent/MX2008011312A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Se describe un compuesto de la estructura. Se describe este compuesto y su uso para preparar medicinas útiles en el tratamiento de trastornos neurodegenerativos.
MX2008011312A 2006-03-07 2007-03-05 Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos. MX2008011312A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77994006P 2006-03-07 2006-03-07
PCT/US2007/005645 WO2007103347A1 (en) 2006-03-07 2007-03-05 Meridamycin analogues for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
MX2008011312A true MX2008011312A (es) 2008-09-12

Family

ID=38289934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011312A MX2008011312A (es) 2006-03-07 2007-03-05 Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos.

Country Status (19)

Country Link
US (1) US7745457B2 (es)
EP (1) EP1991551A1 (es)
JP (1) JP2009529049A (es)
KR (1) KR20080099317A (es)
CN (1) CN101426796A (es)
AR (1) AR059738A1 (es)
AU (1) AU2007223962A1 (es)
BR (1) BRPI0708611A2 (es)
CA (1) CA2643350A1 (es)
CR (1) CR10272A (es)
EC (1) ECSP088718A (es)
IL (1) IL193414A0 (es)
MX (1) MX2008011312A (es)
NO (1) NO20083695L (es)
PE (1) PE20081550A1 (es)
RU (1) RU2008132779A (es)
TW (1) TW200804400A (es)
WO (1) WO2007103347A1 (es)
ZA (1) ZA200807678B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1828202T3 (da) * 2004-12-20 2012-05-07 Wyeth Llc Rapamycinanaloge samt deres anvendelse ved behandling af neurologiske, proliferative og inflammatoriske lidelser
US7273874B2 (en) * 2004-12-20 2007-09-25 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302016D0 (en) 1993-02-02 1993-03-17 Sandoz Ltd Compounds
GB9318144D0 (en) 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
AU2005219822A1 (en) * 2004-03-02 2005-09-15 Wyeth Macrolides and methods for producing same
US20050197356A1 (en) * 2004-03-02 2005-09-08 Wyeth Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
JP2008501342A (ja) * 2004-06-03 2008-01-24 ワイス 複合ポリケチドを生成するための生合成遺伝子クラスター
US7595187B2 (en) * 2004-11-12 2009-09-29 Wyeth Elaiophylin biosynthetic gene cluster
DK1828202T3 (da) 2004-12-20 2012-05-07 Wyeth Llc Rapamycinanaloge samt deres anvendelse ved behandling af neurologiske, proliferative og inflammatoriske lidelser
US7273874B2 (en) 2004-12-20 2007-09-25 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders

Also Published As

Publication number Publication date
AU2007223962A1 (en) 2007-09-13
CN101426796A (zh) 2009-05-06
WO2007103347A1 (en) 2007-09-13
US20070213525A1 (en) 2007-09-13
JP2009529049A (ja) 2009-08-13
IL193414A0 (en) 2009-05-04
RU2008132779A (ru) 2010-04-20
BRPI0708611A2 (pt) 2011-06-07
AR059738A1 (es) 2008-04-23
US7745457B2 (en) 2010-06-29
NO20083695L (no) 2008-10-03
ECSP088718A (es) 2008-10-31
EP1991551A1 (en) 2008-11-19
CR10272A (es) 2008-10-03
PE20081550A1 (es) 2008-12-31
ZA200807678B (en) 2009-08-26
KR20080099317A (ko) 2008-11-12
TW200804400A (en) 2008-01-16
CA2643350A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
IL184371A (en) Use of an anti il-31ra antibody in the manufacture of a medicament for treating skin disorders
EP1838320A4 (en) CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL PROBLEMS
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
IL178302A (en) Use of Natalizumab in the preparation of a drug to reduce the need for steroid therapy
IL183101A (en) Use of tetrahydrocannabivarin in drug production
EP1985302A4 (en) DRUGS FOR TUMOR THERAPY AND ITS USE
MX339116B (es) Tratamiento de esclerosis tuberosa.
TN2011000291A1 (en) Purine compounds
HK1119070A1 (en) Use of trans-clomiphene in the manufacture of medicines
SG146451A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient
IL190652A0 (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
PT2054045E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor
EP2077838A4 (en) METHODS FOR TREATING A-RELATED DISORDERS AND COMPOSITIONS THEREFOR
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP1757282A4 (en) USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS
MX2008011312A (es) Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos.
ME01951B (me) Upotreba agomelatina za dobijanje lekova namenjenih tretmanu bipolarnih poremećaja
EP2039342A4 (en) MEANS FOR MAINTAINING THE HARDENING TISSUE STRUCTURE
EP1864671A4 (en) USE OF HYDROCHLORIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HYPERTENSION
IL182406A0 (en) Use of an anti-atherothrombotic compound in obtaining medicaments intended for the treatment of vascular disorders
AP2008004391A0 (en) Pharmaceutical composition suitable for the treatment of malaris within one day

Legal Events

Date Code Title Description
FA Abandonment or withdrawal